Division of Emergency and Critical Care Medicine, Department of Acute Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-Ku, Tokyo, 173-8610, Japan.
Department of Emergency and Critical Care Medicine, Nihon University Hospital, Tokyo, Japan.
Eur J Med Res. 2021 Feb 8;26(1):18. doi: 10.1186/s40001-021-00489-8.
Patients with severe COVID-19 have disorders of the respiratory, cardiovascular, coagulation, skeletal muscle, and central nervous systems. These systemic failures may be associated with cytokine release syndrome, characterized by hyperpyrexia, thrombocytopenia, hyperferritinemia, and the elevation of other inflammatory markers. Rhabdomyolysis with high fever is a complication that is rarely found in COVID-19. The exact relations of these clinical conditions in patients with COVID-19 remain unknown.
We present the case of a 36-year-old man with severe COVID-19 complicated by rhabdomyolysis and high fever. After admission, his condition continued to deteriorate, with a high body temperature. On day 9, the patient had elevated creatine kinase and myoglobin levels consistent with rhabdomyolysis (26,046 U/L and 3668 ng/mL, respectively). In addition to viral therapy, he was immediately treated with hydration. However, the patient had persistent fever and elevated creatine kinase levels. The patient was diagnosed with malignant hyperthermia as a late complication of COVID-19, although he had no hereditary predisposition to malignant hyperthermia or neuroleptic malignant syndrome. The administration of dantrolene with muscle relaxation and anti-inflammatory function showed potential efficacy for rhabdomyolysis, high fever, and increased plasma inflammatory markers.
Malignant hyperthermia is triggered by not only anesthetic agents but also viral infections. A possible mechanism of malignant hyperthermia is hypersensitivity of calcium release from the sarcoplasmic reticulum. These include mutations in or the activation of the skeletal muscle ryanodine receptor calcium release channel. Dantrolene is a ryanodine receptor antagonist and is used as an anti-inflammatory agent. The administration of dantrolene showed potential efficacy for rhabdomyolysis, high body temperature due to inflammation, and increased inflammatory markers. The underlying mechanism of the association of rhabdomyolysis and high fever in COVID-19 might be similar to the pathogenesis of malignant hyperthermia.
患有严重 COVID-19 的患者存在呼吸系统、心血管系统、凝血系统、骨骼肌和中枢神经系统紊乱。这些全身衰竭可能与细胞因子释放综合征有关,其特征是高热、血小板减少、高铁蛋白血症和其他炎症标志物升高。伴有高热的横纹肌溶解症是 COVID-19 中很少见的并发症。COVID-19 患者中这些临床情况的确切关系尚不清楚。
我们报告了一例 36 岁男性 COVID-19 患者,并发横纹肌溶解症和高热。入院后,他的病情持续恶化,体温升高。第 9 天,患者的肌酸激酶和肌红蛋白水平升高,符合横纹肌溶解症(分别为 26046 U/L 和 3668ng/mL)。除了病毒治疗外,他立即接受了水化治疗。然而,患者持续发热,肌酸激酶水平升高。尽管该患者没有恶性高热或神经安定恶性综合征的遗传易感性,但仍被诊断为 COVID-19 的晚期并发症恶性高热。肌松和抗炎作用的丹曲林治疗对横纹肌溶解症、高热和增加的血浆炎症标志物显示出潜在疗效。
恶性高热不仅由麻醉剂触发,还可能由病毒感染触发。恶性高热的可能机制是肌浆网钙离子释放的超敏反应。这些包括骨骼肌ryanodine 受体钙释放通道的突变或激活。丹曲林是一种ryanodine 受体拮抗剂,用作抗炎剂。丹曲林治疗对横纹肌溶解症、炎症引起的高热和增加的炎症标志物显示出潜在疗效。COVID-19 中横纹肌溶解症和高热的关联的潜在机制可能与恶性高热的发病机制相似。